Activity ID
15388Expires
December 31, 2027Format Type
EnduringCME Credit
1Fee
$0CME Provider: Clinical Care Options, LLC
Description of CME Course
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Movement Disorders
ABMS Member Board Approvals by Type
ABMS Lifelong Learning CME Activity
Psychiatry and Neurology
Commercial Support?
YesNOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Educational Objectives
Analyze the pharmacologic mechanisms, metabolic pathways, and treatment‑emergent risks associated with antipsychotic medications that contribute to the development of tardive dyskinesia
Compare the pharmacokinetic and pharmacodynamic profiles of available VMAT2 inhibitors
Demonstrate how the characteristics of available VMAT2 inhibitors inform dosing, titration, and clinical decision‑making in TD management
Integrate evidence‑based pharmacologic strategies into individualized treatment plans for TD, considering comorbid psychiatric conditions, concomitant medications, and long‑term therapeutic goals in diverse and complex scenarios
Competencies
Medical Knowledge
CME Credit Type
AMA PRA Category 1 Credit
Practice Setting
Academic Medicine, Inpatient, Outpatient, Rural, Urban, VA/Military
